据Satviki Sanjay报道，印度联邦食品监管机构向Dr. Reddy’s Laboratories Ltd.与Nestle India Ltd.的合资企业发出通知，因其GLP-1补充剂的误导性和模糊宣传。
India’s federal food regulator issued a notice to the joint venture between Dr. Reddy’s Laboratories Ltd. and Nestle India Ltd. for misleading and ambiguous claims about its GLP-1 supplement.
品牌名Celevida GLP+以及诸如“在GLP-1/GIP疗法期间提供高蛋白支持以保持瘦肌肉”和“进口自欧洲以确保纯度”等声明被印度食品安全标准局在周四的Instagram帖子中认定为误导消费者。
The brand name Celevida GLP+ and claims such as “high protein support for lean muscle preservation during GLP-1/GIP therapies” and “imported from Europe for purity” were found to be misleading for consumers, the Food Safety and Standards Authority of India said in an Instagram post Thursday. It also issued notices to sellers including Flipkart India Pvt. and Amazon Seller Services Pvt..
监管机构还向包括Flipkart India Pvt.和Amazon Seller Services Pvt.在内的卖家发出通知。
The firms did not immediately respond to a Bloomberg News request for comment.
该合资企业——Dr. Reddy’s与Nestle Health Science Ltd.——于5月推出了Celevida GLP+——一种高蛋白粉，旨在为在印度使用减肥和糖尿病GLP-1药物的人群提供营养和肌肉质量维护。
The venture called Dr. Reddy’s and Nestle Health Science Ltd. launched Celevida GLP+ — a high protein powder — in May to support nutrition and muscle mass maintenance for people taking weight-loss and diabetes GLP-1 drugs in India.
过去几个月，FSSAI已对印度的虚假宣传公司进行打击，涉及的公司包括Dabur India Ltd.
The FSSAI has cracked down on companies making false claims in India over the past few months, acting against firms including Dabur India Ltd.